Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) saw a large drop in short interest in September. As of September 15th, there was short interest totalling 97,700 shares, a drop of 9.4% from the August 31st total of 107,800 shares. Based on an average daily volume of 2,070,000 shares, the short-interest ratio is currently 0.0 days. Currently, 0.6% of the shares of the company are sold short.
Bluejay Diagnostics Trading Down 9.4 %
NASDAQ:BJDX opened at $0.13 on Tuesday. The company’s 50 day moving average is $0.28 and its two-hundred day moving average is $2.59. The company has a market cap of $42,672.00, a PE ratio of 0.00 and a beta of 0.73. Bluejay Diagnostics has a twelve month low of $0.12 and a twelve month high of $38.96.
Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($5.12) earnings per share (EPS) for the quarter.
Institutional Inflows and Outflows
About Bluejay Diagnostics
Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.
Featured Articles
- Five stocks we like better than Bluejay Diagnostics
- Best Aerospace Stocks Investing
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- How to Invest in the Best Canadian Stocks
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.